Camurus Dirección

Dirección controles de criterios 4/4

El CEO de Camurus es Fredrik Tiberg, nombrado en Jan 2003, tiene una permanencia de 21.83 años. posee directamente un 2.82% de las acciones de la empresa, con un valor de SEK951.18M. La antigüedad media del equipo directivo y de la junta directiva es de 5.8 años y 4.5 años, respectivamente.

Información clave

Fredrik Tiberg

Chief Executive Officer (CEO)

SEK 12.1m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	21.8yrs
Participación del CEO	2.8%
Permanencia media de la dirección	5.8yrs
Promedio de permanencia en la Junta Directiva	4.5yrs

Actualizaciones recientes de la dirección

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

May 02

Recent updates

Investors Can Find Comfort In Camurus' (STO:CAMX) Earnings Quality

Nov 15

Camurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Nov 10

What Camurus AB (publ)'s (STO:CAMX) P/S Is Not Telling You

Aug 09

Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts

Jul 19

We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease

Jul 12

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

May 02

Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

Nov 11

We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve

Feb 22

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Fredrik Tiberg en comparación con los beneficios de Camurus?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	SEK 266m
Jun 30 2024	n/a	n/a	SEK 223m
Mar 31 2024	n/a	n/a	SEK 450m
Dec 31 2023	SEK 12m	n/a	SEK 431m
Sep 30 2023	n/a	n/a	SEK 460m
Jun 30 2023	n/a	n/a	SEK 408m
Mar 31 2023	n/a	n/a	SEK 115m
Dec 31 2022	SEK 10m	SEK 6m	SEK 56m
Sep 30 2022	n/a	n/a	SEK 28m
Jun 30 2022	n/a	n/a	-SEK 13m
Mar 31 2022	n/a	n/a	-SEK 69m
Dec 31 2021	SEK 10m	SEK 6m	-SEK 90m
Sep 30 2021	n/a	n/a	-SEK 142m
Jun 30 2021	n/a	n/a	-SEK 156m
Mar 31 2021	n/a	n/a	-SEK 128m
Dec 31 2020	SEK 10m	SEK 5m	-SEK 167m
Sep 30 2020	n/a	n/a	-SEK 174m
Jun 30 2020	n/a	n/a	-SEK 216m
Mar 31 2020	n/a	n/a	-SEK 284m
Dec 31 2019	SEK 8m	SEK 5m	-SEK 290m
Sep 30 2019	n/a	n/a	-SEK 305m
Jun 30 2019	n/a	n/a	-SEK 286m
Mar 31 2019	n/a	n/a	-SEK 266m
Dec 31 2018	SEK 8m	SEK 5m	-SEK 235m
Sep 30 2018	n/a	n/a	-SEK 200m
Jun 30 2018	n/a	n/a	-SEK 208m
Mar 31 2018	n/a	n/a	-SEK 187m
Dec 31 2017	SEK 6m	SEK 4m	-SEK 191m

Compensación vs. Mercado: La compensación total ($USD1.09M) de Fredrik está en línea con el promedio de empresas de tamaño similar en el mercado Swedish ($USD1.00M).

Compensación vs. Ingresos: La compensación de Fredrik ha sido consistente con los resultados de la empresa en el último año.

CEO

Fredrik Tiberg (61 yo)

21.8yrs

Permanencia

SEK 12,056,000

Compensación

Mr. Fredrik Tiberg has been Independent Director of Amniotics AB (publ) since 2021. He has been the Chief Executive Officer and President of Camurus AB (publ) since 2003. Mr. Tiberg serves as Chief Executi...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Fredrik Tiberg	President	21.8yrs	SEK 12.06m	2.82% SEK 951.2m
Jon U. Alonso	Chief Financial Officer	2.8yrs	sin datos	0.0025% SEK 832.3k
Torsten Malmstrom	Chief Technology Officer	11.8yrs	sin datos	0.060% SEK 20.3m
Rein Piir	Vice President of Investor Relations	9.8yrs	sin datos	sin datos
Bo A. TarrasWahlberg	VP of Legal & Group General Counsel	less than a year	sin datos	sin datos
Maria Lundqvist	Global Head of Human Resources	3.6yrs	sin datos	sin datos
Markus Johnsson	Senior Vice President of R&D	no data	sin datos	0.036% SEK 12.0m
Fredrik Joabsson	Chief Business Development Officer	5.8yrs	sin datos	0.068% SEK 23.0m
Richard Jameson	Chief Commercial Officer	8.4yrs	sin datos	0.050% SEK 16.7m
Alberto Pedroncelli	Chief Medical Officer	1.4yrs	sin datos	sin datos

5.8yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CAMX es experimentado (5.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Fredrik Tiberg	President	22.8yrs	SEK 12.06m	2.82% SEK 951.2m
Jakob Lindberg	Independent Director	3.5yrs	SEK 350.00k	sin datos
Per-Olof Wallstrom	Independent Chairman of the Board	14.8yrs	SEK 750.00k	0.17% SEK 58.6m
Behshad Sheldon	Independent Director	6.5yrs	SEK 350.00k	0.0017% SEK 572.9k
Hege Hellstrom	Independent Director	4.5yrs	SEK 375.00k	0.0055% SEK 1.9m
Stefan Persson	Director	2.5yrs	SEK 375.00k	0.0053% SEK 1.8m
Erika Johnsson	Director	1.5yrs	SEK 450.00k	0.0010% SEK 347.1k

4.5yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de CAMX se considera experimentada (4.5 años de antigüedad promedio).

Camurus Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Camurus AB (publ), Annual General Meeting, May 27, 2025

President exercised options to buy kr81m worth of stock.

President recently sold kr39m worth of stock

Chief Technology Officer recently sold kr6.8m worth of stock

Chief Technology Officer recently sold kr845k worth of stock

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

Recent updates

Investors Can Find Comfort In Camurus' (STO:CAMX) Earnings Quality

Camurus AB (publ), Annual General Meeting, May 27, 2025

Camurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Camurus AB (publ) to Report Q1, 2025 Results on May 15, 2025

Camurus Provides Regulatory Update on the US NDA for CAM2029 in Acromegaly

President exercised options to buy kr81m worth of stock.

President recently sold kr39m worth of stock

What Camurus AB (publ)'s (STO:CAMX) P/S Is Not Telling You

New minor risk - Insider selling

Chief Technology Officer recently sold kr6.8m worth of stock

Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts

Second quarter 2024 earnings: EPS misses analyst expectations

Camurus Announces Positive Phase 3 Results from the Acroinnova 2 Study of Octreotide Sc Depot (Cam2029) in Acromegaly Patients

We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease

Camurus Announces the Publication in JAMA Network Open of A New Post H Holes Analysis from A 24-Week Randomized, Double-Blind, Phase 3 Study

Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot (Cam2029) for the Treatment of Acromegaly

Chief Technology Officer recently sold kr845k worth of stock

Consensus EPS estimates increase by 18%

First quarter 2024 earnings released: EPS: kr1.36 (vs kr1.06 in 1Q 2023)

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects

Camurus AB (Publ) Announces Board Resignations

Full year 2023 earnings: EPS misses analyst expectations

Camurus AB (Publ) Announces FDA Acceptance of NDA Submission for Oclaiz™ for Treatment of Acromegaly

Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality

Consensus EPS estimates fall by 39%

With EPS Growth And More, Camurus (STO:CAMX) Makes An Interesting Case

Full year 2023 earnings: EPS misses analyst expectations

Camurus AB Provides Earnings Guidance for the Full Year 2024

Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024

Camurus AB (Publ) Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease

Investor sentiment deteriorates as stock falls 15%

Price target increased by 8.2% to kr550

Camurus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.09 billion.

Camurus AB (publ) Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly

Camurus AB (publ) (STO:CAMX) Investors Are Less Pessimistic Than Expected

President exercised options to buy kr86m worth of stock.

Camurus AB Announces Completed Enrollment in the Phase 3 SORENTO Study of CAM2029 in Patients with Neuroendocrine Tumors

Price target increased by 16% to kr471

Investor sentiment improves as stock rises 20%

Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

Camurus AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.1% to kr351

Camurus AB (Publ) Raises Earnings Guidance for the Year 2023

Camurus AB (publ), Annual General Meeting, May 08, 2024

Insider recently sold kr295k worth of stock

Camurus Announces US Launch of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder by Braeburn

Camurus AB (Publ) Provides Earnings Outlook for the Year 2023

New major risk - Earnings quality

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Camurus Announces New Phase 3 Data Recalling Long-Term Safety and Efficacy of Octreotide Sc Depot (Cam2029) in Patients with Acromegaly

Camurus Announces Positive Topline Results from A 24-Week Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, Acromegaly

President recently sold kr23m worth of stock

Camurus Announces FDA Approval of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder

Consensus EPS estimates increase by 21%

Consensus EPS estimates increase by 25%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Camurus AB (Publ) Elects Erika Söderberg Johnsson as Board Member

We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve

Price target decreased by 7.3% to kr287

Third quarter 2022 earnings released: EPS: kr0.63 (vs kr0.11 loss in 3Q 2021)

Consensus EPS estimates increase by 17%

Camurus AB (Publ) Provides Earnings Guidance for the Year 2023

Consensus forecasts updated

Camurus Announces PDUFA Date for Brixadi NDA for the Treatment of Opioid Use Disorder in the US

Forecast to breakeven in 2022

Price target increased to kr305